Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
African Trypanosomiasis
The DNDi Project of the Year - the Development of Fexinidazole to Treat Sleeping Sickness: Accelera recognised as key partner in the development of a new therapy
July 18th, 2008
The development of fexinidazole for the treatment of African trypanosomiasis, commonly known as "sleeping sickness", by DNDi (Drugs for Neglected Diseases initiative), along with Accelera, a business unit of Nerviano Medical Sciences (NMS), is to be honoured as one of DNDi's Success Stories of the Year. The award will be conferred today in New York, at the prestigious headquarters of the New York Academy of Sciences, during the first annual Stakeholders' Meeting of DNDi. Accelera is recognised as DNDi's key partner in the non-clinical development of fexinidazole. "We are proud to receive this recognition," comments Dr. Marco Brughera – Vice President of Accelera – "and...
Source: Health Business Week (2008-07-18)
|
